CardioInnovate360™
BioPharma Research Platform
For the Discovery, Development, and Validation of Next Generation Cardiovascular Solutions
Epigenetics-based therapies are the next evolution in cardiovascular care and treatment, offering unprecedented opportunities to target the underlying mechanisms of cardiovascular disease.
CardioInnovate360 leverages AI and epigenetics to enable and accelerate the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
Core Capabilities of the CardioInnovate360 Platform
1
1. Novel Biomakers
Identify novel epigenetic and genetic biomarkers and pathways implicated in the pathogenesis of cardiovascular disease and associated co-morbidities.
2. Clinical Trials Optimization
Stratify patients more effectively for clinical trials by selecting those with a higher likelihood of responding to the investigational therapy or by providing more granular outcomes.
2
3
3. Custom Development
Develop custom post-market surveillance or companion diagnostic tests that are non-invasive and scalable.